PD-L1 positive esophagogastric (EG) cancer is associated with distinct bacteria.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.4568
Abstract: 4568Background: Pembrolizumab is approved for chemotherapy-refractory PD-L1 CPS >1 mEG cancer. In clinical trials, pts with MSI-H, EBV+ and PD-L1 CPS >10 EG cancers derive the greatest benefit with... read more here.
Keywords: positive esophagogastric; distinct bacteria; esophagogastric cancer; cancer ... See more keywords